This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Krieger, J. A Articles by Rabinowitz, I. Search for Related Content PubMed Articles by Krieger, J. A Articles by Rabinowitz, I. Social Bookmarking                         What's this?

Necrotizing fasciitis following rituximab therapy

University of New Mexico Health Sciences Center, Cancer Research and Treatment Center, Albuquerque, New Mexico

Jan M Merin, MD

University of New Mexico Health Sciences Center, Cancer Research and Treatment Center, Albuquerque, New Mexico

Ian Rabinowitz, MD

University of New Mexico Health Sciences Center, Cancer Research and Treatment Center, Albuquerque, New Mexico

Rituximab has considerably modified thetherapeutic strategy for B-cell lymphoproliferative malignancies, most notably non-Hodgkin’s lymphoma (NHL). Rituximab, alone or in combination with chemo-therapy, is being used to treat NHL with limited toxicity. We report two cases, one fatal, of necrotizing fasciitis following the use of rituximab in patients with NHL. No obvious predisposing factors were noted in either case. Practitioners need to beaware of this rare side effect and take prompt and aggressive action at the first onset of symptoms.

Key Words: necrotizing fasciitis • non-Hodgkin’s lymphoma • rituximab

Journal of Oncology Pharmacy Practice, Vol. 8, No. 4, 127-129 (2002)
DOI: 10.1191/1078155202jp097oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?